NCT04786262: An ongoing trial by Vertex Pharmaceuticals Incorporated
This trial is ongoing. It must report results 2 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04786262 |
|---|---|
| Title | A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 29, 2021 |
| Completion date | June 30, 2027 |
| Required reporting date | June 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |